| Market Cap | 94.40B | P/E | 17.12 | EPS this Y | -40.30% | Ern Qtrly Grth | - |
| Income | 485M | Forward P/E | 11.63 | EPS next Y | 90.70% | 50D Avg Chg | -2.00% |
| Sales | 27.45B | PEG | 3.36 | EPS past 5Y | 1.66% | 200D Avg Chg | -6.00% |
| Dividend | 4.00% | Price/Book | 4.50 | EPS next 5Y | 5.38% | 52W High Chg | -16.00% |
| Recommedations | 2.50 | Quick Ratio | 0.82 | Shares Outstanding | 1.25B | 52W Low Chg | 25.00% |
| Insider Own | 0.11% | ROA | 10.50% | Shares Float | 1.24B | Beta | 0.24 |
| Inst Own | 87.95% | ROE | 2.39% | Shares Shorted/Prior | 21.16M/22.57M | Price | 75.68 |
| Gross Margin | 77.52% | Profit Margin | 1.77% | Avg. Volume | 5,671,716 | Target Price | 81.29 |
| Oper. Margin | 34.43% | Earnings Date | Aug 8 | Volume | 5,249,684 | Change | 0.00% |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Barclays | Equal-Weight | Apr 29, 24 |
| TD Cowen | Buy | Apr 26, 24 |
| Morgan Stanley | Equal-Weight | Apr 26, 24 |
| RBC Capital | Sector Perform | Apr 26, 24 |
| Needham | Hold | Apr 26, 24 |
| HSBC | Hold | Apr 24, 24 |
| Oppenheimer | Outperform | Apr 19, 24 |
| UBS | Neutral | Apr 17, 24 |
| Wells Fargo | Equal-Weight | Mar 4, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Offi.. Chief Financial Officer | Jan 16 | Sell | 85.78 | 5,000 | 428,900 | 101,534 | 01/17/24 |
| Mercier Johanna | Chief Commercial Off.. Chief Commercial Officer | Jan 09 | Sell | 85.23 | 8,242 | 702,466 | 82,729 | 01/10/24 |
| Parsey Merdad | Chief Medical Office.. Chief Medical Officer | Sep 12 | Sell | 76.99 | 1,501 | 115,562 | 70,130 | 09/13/23 |
| Dickinson Andrew D | Chief Financial Offi.. Chief Financial Officer | Jul 20 | Sell | 80.00 | 5,000 | 400,000 | 107,587 | 07/21/23 |
| Parsey Merdad | Chief Medical Office.. Chief Medical Officer | Jun 13 | Sell | 76.90 | 1,485 | 114,197 | 29,402 | 06/14/23 |
| Parsey Merdad | Chief Medical Office.. Chief Medical Officer | Mar 13 | Sell | 78.99 | 6,126 | 483,893 | 70,130 | 03/14/23 |
| Lofton Kevin E | Director Director | Mar 09 | Option | 52.38 | 8,442 | 442,192 | 8,442 | 03/10/23 |
| Parsey Merdad | Chief Medical Office.. Chief Medical Officer | Mar 01 | Sell | 79.9619 | 12,984 | 1,038,225 | 70,130 | 03/02/23 |
| Parsey Merdad | Chief Medical Office.. Chief Medical Officer | Dec 30 | Sell | 85.33 | 553 | 47,187 | 45,556 | 01/03/23 |
| Wilfong Diane E. | SVP, Controller & CA.. SVP, Controller & CAO | Nov 01 | Option | 72.7 | 16,255 | 1,181,738 | 44,588 | 11/02/22 |
| Wilfong Diane E. | SVP, Controller & CA.. SVP, Controller & CAO | Nov 01 | Sell | 79.25 | 16,255 | 1,288,209 | 28,333 | 11/02/22 |
| Lofton Kevin E | Director Director | Apr 28 | Option | 25.625 | 16,322 | 418,251 | 90,525 | 04/29/22 |
| Pletcher Brett A | EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel | Mar 10 | Sell | 58.24 | 3,634 | 211,644 | 32,576 | 03/14/22 |
| Pletcher Brett A | EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel | Feb 09 | Sell | 63.89 | 1,691 | 108,038 | 32,576 | 02/11/22 |
| Pletcher Brett A | EVP,Corp Affairs & G.. EVP,Corp Affairs & Gen Counsel | Feb 01 | Sell | 68.5358 | 14,061 | 963,682 | 32,576 | 02/02/22 |
| Wilfong Diane E. | SVP, Controller & CA.. SVP, Controller & CAO | Aug 18 | Sell | 72.5 | 13,610 | 986,725 | 20,398 | 08/18/21 |
| Wilfong Diane E. | SVP, Controller & CA.. SVP, Controller & CAO | Aug 18 | Option | 67.56 | 13,610 | 919,492 | 34,008 | 08/18/21 |
| Whitley Richard James | Director Director | May 04 | Option | 20.65 | 20,282 | 418,823 | 51,404 | 05/04/21 |